Greenwich LifeSciences Announces Activation of Clinical Sites and Commencement of Phase III Clinical Trial

Author's Avatar
Aug 11, 2022

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced the following: